The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

SANDOSTATIN 50 microgram/1 ml, solution for injection/infusion

Novartis Ireland LimitedPA0896/028/001

Main Information

Trade NameSANDOSTATIN 50 microgram/1 ml, solution for injection/infusion
Active SubstancesOctreotide
Dosage FormSolution for injection/infusion
Licence HolderNovartis Ireland Limited
Licence NumberPA0896/028/001

Group Information

ATC CodeH01CB Somatostatin and analogues
H01CB02 octreotide


License statusAuthorised
Licence Issued18/11/1988
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back